Kuo-kai B. Chin

Hematology

1275 York Ave
New York, NY 10065

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Blinatumomab administration in the outpatient setting: Safety and health care utilization.

Blinatumomab administration in the outpatient setting: Safety and health care utilization.

Journal: Cancer

Published: May 01, 2026

Overcoming MEN1-mediated resistance with menin inhibitor switching in KMT2A-rearranged acute myeloid leukemia.

Overcoming MEN1-mediated resistance with menin inhibitor switching in KMT2A-rearranged acute myeloid leukemia.

Journal: Leukemia

Published: January 19, 2026

Curative strategies for high-risk acute promyelocytic leukemia.

Curative strategies for high-risk acute promyelocytic leukemia.

Journal: Current opinion in oncology

Published: October 01, 2025

Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.

Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.

Journal: Blood advances

Published: August 22, 2025

Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.

Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.

Journal: Blood advances

Published: August 22, 2025

Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs.

Outpatient cytarabine consolidation in acute myeloid leukemia safely reduces hospitalization time and treatment costs.

Journal: Cancer

Published: May 20, 2025

Barriers to Chimeric Antigen Receptor T-Cell Therapy.

Barriers to Chimeric Antigen Receptor T-Cell Therapy.

Journal: JAMA oncology

Published: May 15, 2025

Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction.

Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction.

Journal: Blood advances

Published: November 12, 2024

HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML.

HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML.

Journal: Leukemia & lymphoma

Published: October 14, 2024

Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis.

Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis.

Journal: Blood advances

Published: July 29, 2024

Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia.

Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia.

Journal: Blood neoplasia

Published: May 30, 2024

Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience.

Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience.

Journal: Transplantation and cellular therapy

Published: July 05, 2021

Showing 1-12 of 21

Last Updated: 09/26/2026